Literature DB >> 16462405

HAART to heart: HIV-related cardiomyopathy and other cardiovascular complications.

Cynthia L Dakin1, Catherine A O'Connor, Carol A Patsdaughter.   

Abstract

More than one million Americans have been diagnosed with human immunodeficiency virus (HIV). Advances in prevention and treatment of HIV have led to an increased life expectancy for patients with HIV infection. Due to their increased life span, HIV+ patients are now presenting to hospitals with an increased number of diverse late-stage complications, such as cardiomyopathy and other cardiovascular conditions. These complications are as a direct or indirect result of HIV disease, HIV treatment modalities, comorbid conditions, dietary and lifestyle factors, and unknown etiologies. Cardiac complications, particularly HIV-related dilated cardiomyopathy, are potentially life-threatening diagnoses, with symptoms that may be minimized with appropriate cardiac-specific assessments and treatments, patient teaching, and collaboration among nurses caring for the HIV-positive client with cardiac disease.

Entities:  

Mesh:

Year:  2006        PMID: 16462405     DOI: 10.1097/00044067-200601000-00003

Source DB:  PubMed          Journal:  AACN Clin Issues        ISSN: 1079-0713


  2 in total

1.  Integrated care of an aging HIV-infected male-to-female transgender patient.

Authors:  Pansy Ferron; Sandra Young; Catherine Boulanger; Allan Rodriguez; Jose Moreno
Journal:  J Assoc Nurses AIDS Care       Date:  2010-03-19       Impact factor: 1.354

2.  Cardiac status of children infected with human immunodeficiency virus who are receiving long-term combination antiretroviral therapy: results from the Adolescent Master Protocol of the Multicenter Pediatric HIV/AIDS Cohort Study.

Authors:  Steven E Lipshultz; Paige L Williams; James D Wilkinson; Erin C Leister; Russell B Van Dyke; William T Shearer; Kenneth C Rich; Rohan Hazra; Jonathan R Kaltman; Denise L Jacobson; Laurie B Dooley; Gwendolyn B Scott; Nicole Rabideau; Steven D Colan
Journal:  JAMA Pediatr       Date:  2013-06       Impact factor: 16.193

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.